When The Outcome of An Appraisal Is Not Nice: A Review Of Nice Appeals

OBJECTIVES: The National Institute for Health and Care Excellence (NICE) provides stakeholders to health technology appraisals the option to appeal the decision. We conducted an analysis of past appeals to review the appraisal appeal process by time, therapeutic area, number and type of appellants,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Value in health 2017-10, Vol.20 (9), p.A693
Hauptverfasser: O'Day, K, Campbell, DJ, Meyer, KL
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 9
container_start_page A693
container_title Value in health
container_volume 20
creator O'Day, K
Campbell, DJ
Meyer, KL
description OBJECTIVES: The National Institute for Health and Care Excellence (NICE) provides stakeholders to health technology appraisals the option to appeal the decision. We conducted an analysis of past appeals to review the appraisal appeal process by time, therapeutic area, number and type of appellants, grounds of the appeal, and success of the appeal. METHODS: Appeals starting from the year 2000 were identified on the NICE website. Appeal decision documents were reviewed to obtain date of appeal, therapeutic area, number of appellants, type of appellant, grounds of the appeal, and outcome of the appeal (ie, whether it was dismissed or upheld). Results were tabulated in an Excel spreadsheet and descriptive statistics were compiled. RESULTS: A total of 87 past appeals were identified and appeal decisions were available for 75 of the appeals. The annual number of appeals peaked between 2006 and 2008. The most common therapeutic areas of appeals were oncology (39%), rheumatology (16%), and endocrinology (12%).There were a mean of 2.4 appellants per appeal. Manufacturers were the most common appellant (47%), followed by professional group (22%), patient group (22%), clinical (5%), and other (3%).The most frequent ground for an appeal was unreasonable evidence (92%), followed by failure to be fair (64%), and exceeded powers (23%). Forty-two (56%) of the appeal decisions were dismissed on all grounds, while the remaining 33 (44%) were upheld on one or more grounds. Failure to be fair was the most common ground for upholding the appeal (38%), followed by unreasonable evidence (34%), and exceeded powers (7%). CONCLUSIONS: Manufacturers are the most common appellant in NICE appeals, with unreasonable evidence being the most common ground for the appeal. However, failure to be fair is the ground for appeal most likely to be upheld.
doi_str_mv 10.1016/j.jval.2017.08.1776
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2113726487</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2113726487</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1676-651a3b17343cf7454e603a194393ede5679df4f397ba6b7fd3124bed048b45de3</originalsourceid><addsrcrecordid>eNotkF1Lw0AQRRdRsFZ_gS8LPifuZPYj8S0Uq4XSglR8XDbJLE1om5htK_57E_XpDpfDXDiM3YOIQYB-bOLm7HZxIsDEIo3BGH3BJqASGUmDeDncIksjFKCu2U0IjRBCY6ImbP6xpQPfbImvT8ey3RNvPc8PPO-63tXB7fgi8FV75Ku6pCee8zc61_TF1_63GTlyu3DLrvwQdPefU_Y-f97MXqPl-mUxy5dRCdroSCtwWIBBiaU3UknSAh1kEjOkipQ2WeWlx8wUThfGVwiJLKgSMi2kqgin7OHvb9e3nycKR9u0p_4wTNoEAE2iZWoGCv-osm9D6Mnbrq_3rv-2IOwozDZ2FGZHYVakdhSGP2ZTXIU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2113726487</pqid></control><display><type>article</type><title>When The Outcome of An Appraisal Is Not Nice: A Review Of Nice Appeals</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>O'Day, K ; Campbell, DJ ; Meyer, KL</creator><creatorcontrib>O'Day, K ; Campbell, DJ ; Meyer, KL</creatorcontrib><description>OBJECTIVES: The National Institute for Health and Care Excellence (NICE) provides stakeholders to health technology appraisals the option to appeal the decision. We conducted an analysis of past appeals to review the appraisal appeal process by time, therapeutic area, number and type of appellants, grounds of the appeal, and success of the appeal. METHODS: Appeals starting from the year 2000 were identified on the NICE website. Appeal decision documents were reviewed to obtain date of appeal, therapeutic area, number of appellants, type of appellant, grounds of the appeal, and outcome of the appeal (ie, whether it was dismissed or upheld). Results were tabulated in an Excel spreadsheet and descriptive statistics were compiled. RESULTS: A total of 87 past appeals were identified and appeal decisions were available for 75 of the appeals. The annual number of appeals peaked between 2006 and 2008. The most common therapeutic areas of appeals were oncology (39%), rheumatology (16%), and endocrinology (12%).There were a mean of 2.4 appellants per appeal. Manufacturers were the most common appellant (47%), followed by professional group (22%), patient group (22%), clinical (5%), and other (3%).The most frequent ground for an appeal was unreasonable evidence (92%), followed by failure to be fair (64%), and exceeded powers (23%). Forty-two (56%) of the appeal decisions were dismissed on all grounds, while the remaining 33 (44%) were upheld on one or more grounds. Failure to be fair was the most common ground for upholding the appeal (38%), followed by unreasonable evidence (34%), and exceeded powers (7%). CONCLUSIONS: Manufacturers are the most common appellant in NICE appeals, with unreasonable evidence being the most common ground for the appeal. However, failure to be fair is the ground for appeal most likely to be upheld.</description><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1016/j.jval.2017.08.1776</identifier><language>eng</language><publisher>Lawrenceville: Elsevier Science Ltd</publisher><subject>Appraisal ; Appraisals ; Endocrinology ; Health care ; Medical technology ; Millennium ; Oncology ; Rheumatology ; Stakeholders ; Statistical analysis</subject><ispartof>Value in health, 2017-10, Vol.20 (9), p.A693</ispartof><rights>Copyright Elsevier Science Ltd. Oct/Nov 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1676-651a3b17343cf7454e603a194393ede5679df4f397ba6b7fd3124bed048b45de3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904,30978</link.rule.ids></links><search><creatorcontrib>O'Day, K</creatorcontrib><creatorcontrib>Campbell, DJ</creatorcontrib><creatorcontrib>Meyer, KL</creatorcontrib><title>When The Outcome of An Appraisal Is Not Nice: A Review Of Nice Appeals</title><title>Value in health</title><description>OBJECTIVES: The National Institute for Health and Care Excellence (NICE) provides stakeholders to health technology appraisals the option to appeal the decision. We conducted an analysis of past appeals to review the appraisal appeal process by time, therapeutic area, number and type of appellants, grounds of the appeal, and success of the appeal. METHODS: Appeals starting from the year 2000 were identified on the NICE website. Appeal decision documents were reviewed to obtain date of appeal, therapeutic area, number of appellants, type of appellant, grounds of the appeal, and outcome of the appeal (ie, whether it was dismissed or upheld). Results were tabulated in an Excel spreadsheet and descriptive statistics were compiled. RESULTS: A total of 87 past appeals were identified and appeal decisions were available for 75 of the appeals. The annual number of appeals peaked between 2006 and 2008. The most common therapeutic areas of appeals were oncology (39%), rheumatology (16%), and endocrinology (12%).There were a mean of 2.4 appellants per appeal. Manufacturers were the most common appellant (47%), followed by professional group (22%), patient group (22%), clinical (5%), and other (3%).The most frequent ground for an appeal was unreasonable evidence (92%), followed by failure to be fair (64%), and exceeded powers (23%). Forty-two (56%) of the appeal decisions were dismissed on all grounds, while the remaining 33 (44%) were upheld on one or more grounds. Failure to be fair was the most common ground for upholding the appeal (38%), followed by unreasonable evidence (34%), and exceeded powers (7%). CONCLUSIONS: Manufacturers are the most common appellant in NICE appeals, with unreasonable evidence being the most common ground for the appeal. However, failure to be fair is the ground for appeal most likely to be upheld.</description><subject>Appraisal</subject><subject>Appraisals</subject><subject>Endocrinology</subject><subject>Health care</subject><subject>Medical technology</subject><subject>Millennium</subject><subject>Oncology</subject><subject>Rheumatology</subject><subject>Stakeholders</subject><subject>Statistical analysis</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNotkF1Lw0AQRRdRsFZ_gS8LPifuZPYj8S0Uq4XSglR8XDbJLE1om5htK_57E_XpDpfDXDiM3YOIQYB-bOLm7HZxIsDEIo3BGH3BJqASGUmDeDncIksjFKCu2U0IjRBCY6ImbP6xpQPfbImvT8ey3RNvPc8PPO-63tXB7fgi8FV75Ku6pCee8zc61_TF1_63GTlyu3DLrvwQdPefU_Y-f97MXqPl-mUxy5dRCdroSCtwWIBBiaU3UknSAh1kEjOkipQ2WeWlx8wUThfGVwiJLKgSMi2kqgin7OHvb9e3nycKR9u0p_4wTNoEAE2iZWoGCv-osm9D6Mnbrq_3rv-2IOwozDZ2FGZHYVakdhSGP2ZTXIU</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>O'Day, K</creator><creator>Campbell, DJ</creator><creator>Meyer, KL</creator><general>Elsevier Science Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope></search><sort><creationdate>201710</creationdate><title>When The Outcome of An Appraisal Is Not Nice: A Review Of Nice Appeals</title><author>O'Day, K ; Campbell, DJ ; Meyer, KL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1676-651a3b17343cf7454e603a194393ede5679df4f397ba6b7fd3124bed048b45de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Appraisal</topic><topic>Appraisals</topic><topic>Endocrinology</topic><topic>Health care</topic><topic>Medical technology</topic><topic>Millennium</topic><topic>Oncology</topic><topic>Rheumatology</topic><topic>Stakeholders</topic><topic>Statistical analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>O'Day, K</creatorcontrib><creatorcontrib>Campbell, DJ</creatorcontrib><creatorcontrib>Meyer, KL</creatorcontrib><collection>CrossRef</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>O'Day, K</au><au>Campbell, DJ</au><au>Meyer, KL</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>When The Outcome of An Appraisal Is Not Nice: A Review Of Nice Appeals</atitle><jtitle>Value in health</jtitle><date>2017-10</date><risdate>2017</risdate><volume>20</volume><issue>9</issue><spage>A693</spage><pages>A693-</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><abstract>OBJECTIVES: The National Institute for Health and Care Excellence (NICE) provides stakeholders to health technology appraisals the option to appeal the decision. We conducted an analysis of past appeals to review the appraisal appeal process by time, therapeutic area, number and type of appellants, grounds of the appeal, and success of the appeal. METHODS: Appeals starting from the year 2000 were identified on the NICE website. Appeal decision documents were reviewed to obtain date of appeal, therapeutic area, number of appellants, type of appellant, grounds of the appeal, and outcome of the appeal (ie, whether it was dismissed or upheld). Results were tabulated in an Excel spreadsheet and descriptive statistics were compiled. RESULTS: A total of 87 past appeals were identified and appeal decisions were available for 75 of the appeals. The annual number of appeals peaked between 2006 and 2008. The most common therapeutic areas of appeals were oncology (39%), rheumatology (16%), and endocrinology (12%).There were a mean of 2.4 appellants per appeal. Manufacturers were the most common appellant (47%), followed by professional group (22%), patient group (22%), clinical (5%), and other (3%).The most frequent ground for an appeal was unreasonable evidence (92%), followed by failure to be fair (64%), and exceeded powers (23%). Forty-two (56%) of the appeal decisions were dismissed on all grounds, while the remaining 33 (44%) were upheld on one or more grounds. Failure to be fair was the most common ground for upholding the appeal (38%), followed by unreasonable evidence (34%), and exceeded powers (7%). CONCLUSIONS: Manufacturers are the most common appellant in NICE appeals, with unreasonable evidence being the most common ground for the appeal. However, failure to be fair is the ground for appeal most likely to be upheld.</abstract><cop>Lawrenceville</cop><pub>Elsevier Science Ltd</pub><doi>10.1016/j.jval.2017.08.1776</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1098-3015
ispartof Value in health, 2017-10, Vol.20 (9), p.A693
issn 1098-3015
1524-4733
language eng
recordid cdi_proquest_journals_2113726487
source Applied Social Sciences Index & Abstracts (ASSIA); Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Appraisal
Appraisals
Endocrinology
Health care
Medical technology
Millennium
Oncology
Rheumatology
Stakeholders
Statistical analysis
title When The Outcome of An Appraisal Is Not Nice: A Review Of Nice Appeals
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T10%3A33%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=When%20The%20Outcome%20of%20An%20Appraisal%20Is%20Not%20Nice:%20A%20Review%20Of%20Nice%20Appeals&rft.jtitle=Value%20in%20health&rft.au=O'Day,%20K&rft.date=2017-10&rft.volume=20&rft.issue=9&rft.spage=A693&rft.pages=A693-&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1016/j.jval.2017.08.1776&rft_dat=%3Cproquest_cross%3E2113726487%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2113726487&rft_id=info:pmid/&rfr_iscdi=true